BBS Faculty Member - Catherine Wu

Catherine Wu

Department of Medicine

Dana Farber Cancer Institute
Dana Building, Room 540
44 Binney St.
Boston, MA 02115
Tel: 617-632-5943
Fax: 617-632-6380
Email: cwu@partners.org
Visit my lab page here.



Dr. Wu’s laboratory focuses on dissecting the underlying mechanisms of pathobiology of chronic lymphocytic leukemia (CLL) as a means to more rationally generate effective therapies, including immune-based treatments, for this common adult leukemia. She has been principal investigator of several center-initiated clinical trials, including an ongoing study that examines the effects of a personal whole tumor cell-based vaccine on outcomes following allogeneic hematopoietic stem cell transplant for the treatment of CLL. A major priority of her studies is the identification of tumor-specific antigens that would allow effective tumor targeting without collateral toxicity. She has been using exome and transcriptome sequencing technologies to identify unique mutated leukemia antigens that arise from individual-specific genetic alterations within a tumor and that could be potentially targeted immunologically, thus paving the way for developing personalized tumor vaccines. Through large-scale genome analysis of chronic lymphocytic leukemia, her laboratory has further discovered key mutated genes and pathways involved in CLL. Other ongoing studies in her laboratory focus on: (a) systematic analyses to couple tumor genotype with phenotype; (b) understanding CLL tumor heterogeneity; and (c) mechanistic studies of novel CLL driver genes.




































Last Update: 1/13/2014



Publications

Wang L*, Lawrence MS*, Wan YZ* Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, Deluca DS, Zhang L, Zhang W, Vartanov A, Fernandes SM, Goldstein NR, Folco EG, Cibulskis K, Tesar B, Sievers QL, Shefler E, Gabriel S, Hacohen N, Reed R, Meyerson M, Golub TR, Lander ES, Neuberg D, Brown JR*, Getz G*, WU CJ*. SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia. N Engl J Med 2011;365(26):2497-506 (* denotes equal contributors)

Lin Y*, Zhang L*, Cai AX, Lee M, Zhang W, Neuberg D, Canning CM, Soiffer RJ, Alyea AP, Ritz J, Hacohen N, Means TK,
WU CJ. Effective post-transplant anti-tumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest 2011; 121:1574-84. (* denotes equal contributors)

Biernacki MA, Tai YT, Zhang GL, Alonso A, Zhang W, Prabhala R, Zhang L, Munshi N, Neuberg D, Soiffer RJ, Ritz J, Alyea EP, Brusic V, Anderson KC,
WU CJ. Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood 2012 119(13):3142-50.

Chapman M, Warren EH 3rd,
WU CJ. Applications of next-generation sequencing to blood and marrow transplantation. Biol Blood Marrow Transplant 2012 18: S151-60.

Landau DA*, Carter SL*, Stojanov P*, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan YZ, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, Cibulskis K, Tesar B, Gabriel S, Hacohen N, Meyerson M, Lander ES, Neuberg D, Brown JR, Getz G*,
WU CJ* Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152(4):714-26.

Hacohen N, Fritsch EF, Carter TA, Lander ES,
WU CJ. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunology Research (in press).

Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough S, Zeng WY, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP,
WU CJ. Autologous CLL cell vaccination early after transplant induces leukemia –specific T cells. J Clin Invest (in press)

Shalek AK, Gaublomme JT, Wang L, Yosef N, Chevrier N, Andersen MS, Robinson JT, Pochet N, Neuberg D, Gertner RS, Amit I, Brown JR, Hacohen N, Regev A,
Wu CJ, Park H. Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. Nano Lett. 2012 Dec 12;12(12):6498-504. PMC3521500



© 2013 by the President and Fellows of Harvard College